On September 15th, the construction of the second phase of the heavy ion radiotherapy system with fully independent intellectual property rights was accelerated in Jinan, China, in response to the 14th Five Year Plan and the construction of a strong country supported by science and technology. This large-scale high-end medical equipment, which has transformed from a large scientific device, has entered multiple cities such as Wuwei, Lanzhou, Putian, and Wuhan with high efficiency and precision in tumor treatment, becoming a "weapon" for cancer treatment and a vivid portrayal of technological innovation safeguarding people's health. General Secretary Xi Jinping emphasized the strategic orientation of adhering to the "four orientations", facing the forefront of world science and technology, the main battlefield of the economy, major national needs, and people's lives and health, strengthening the full chain deployment and full field layout of scientific and technological innovation, comprehensively enhancing scientific and technological strength and innovation capabilities. The 14th Five Year Plan clearly proposes to prioritize the development of people's health, adhere to the principle of prevention first, deeply implement the Healthy China Action, improve national health promotion policies, weave a solid national public health protection network, and provide comprehensive and lifelong health services for the people. In the past five years, China's innovation activities in the field of health have entered an unprecedented period of intensive activity. Health technology has moved from "following" to "leading", constantly opening up new tracks and injecting a continuous stream of powerful energy into safeguarding people's health. Paradigm innovation, writing the 'Chinese answer' for health. In April of this year, the hemophilia B gene therapy drug Xinjiuning, developed and produced by a local enterprise in Shanghai, was officially approved for market. This is China's first gene replacement therapy drug, which can deliver the human coagulation factor IX gene to liver cells, continuously express coagulation factors, and solve the problem of continuous bleeding in 'glass humans'. General Secretary Xi Jinping emphasized the need to adhere to the principle of putting people first and life first, and to develop and produce more "Chinese medicines" that are suitable for the inheritance of Chinese people's life genes and physical fitness characteristics, especially to strengthen the innovation and development of traditional Chinese medicine inheritance. The bottleneck for the high-quality development of China's biopharmaceutical industry has always been "too much imitation and too little innovation". Strengthening basic cutting-edge research is a key path for China to accelerate its transition from a "pharmaceutical powerhouse" to an "innovative pharmaceutical powerhouse". In recent years, Chinese innovation teams have taken the initiative to "explore new paths" in source innovation. The OpenCGT (Cell and Gene Therapy) platform, led by two industrial funds from Beijing and Daxing districts, has chosen a differentiated path in traditional drug research and development. It uses AI models to predict and create new nanocarriers, breaking through the "boundaries" of precise delivery of biopharmaceuticals and supporting the development of China's original new drug clusters. AI has powerful and efficient learning and analysis capabilities, driving the identification of new mechanisms and targets. ”Chen Kaixian, an academician of the CAS Member, said that many new drugs have rapidly entered the clinical trial stage with the assistance of AI. China's pharmaceutical industry is undergoing revolutionary changes, and the development and marketing of innovative drugs have reached a new level. The backbone forces in the fields of supercomputing and large-scale model development have also ventured into the research and development of innovative drugs. Last year, the National Supercomputing Wuxi Center, in collaboration with Shenwei Shuzhi and Taichu Yuanqi, successfully developed the biopharmaceutical large-scale model SWBind, which can accurately predict the structures of small molecule ligands, nucleic acid molecules, and protein molecules. The breakthrough in the ability of big models not only promotes faster and more accurate early drug discovery, but also helps create a new paradigm of "designing from scratch" and "making something out of nothing" for new drug creation, providing new "ammunition" for tackling difficult and severe diseases. Since the 14th Five Year Plan, multiple "first" and "pioneering" drugs have made breakthrough appearances, accelerating the approval of rare disease drugs and other innovative drugs. China has approved more than 200 innovative drugs, ranking second in the world in terms of pharmaceutical industry scale, and the number of innovative drugs under research accounts for nearly 30% of the world's total. At the same time, in terms of traditional Chinese medicine inheritance, innovation and development, a number of national innovation platforms have been built, such as the national key laboratory, the National Engineering Research Center, and the national medical research industry education integration innovation platform; The National Key R&D Program "Modernization of Traditional Chinese Medicine" and other series of projects continue to support key technology research such as ensuring traditional Chinese medicine resources, ecological cultivation of Chinese medicinal materials, and quality evaluation of traditional Chinese medicine. Yu Yanhong, member of the Party Group of the National Health Commission and Director of the State Administration of Traditional Chinese Medicine, introduced that the current research and development process of new Chinese medicine drugs has significantly accelerated. Since 2021, 57 new Chinese medicine drugs have been approved for market, including 27 ancient classic formula Chinese medicine compound preparations. On August 10th, at the 2025 World Robot Conference, a surgical robot that can accurately "pinch" extremely fine metal wires and manipulate them with ease attracted attention. It is the first intelligent diagnosis and treatment system for intracranial aneurysms in China to obtain the third class certificate for innovative medical devices in the field of neurointerventional surgery. During the 14th Five Year Plan period, a large number of high-end medical equipment will be introduced. Intelligent mobile minimally invasive surgical equipment system, coronary artery intervention surgery control system, cardiac magnetic imaging equipment, X/γ - ray integrated radiotherapy system, globally leading wide body CT, first 5T magnetic resonance equipment... "Around high-end medical equipment, we have overcome technical challenges such as in vivo 3D sensing and remote surgical guidance, and pioneered the intelligent mobile minimally invasive surgical equipment system. ”Yang Shanlin, an academician of the CAE Member, told the Science and Technology Daily that this achievement has become the first equipment (set) in China to meet the needs of high mobility by sea, land and air. It has been promoted to more than 1200 hospitals, exported to more than 50 countries, and won 172 intellectual property rights and multiple awards. General Secretary Xi Jinping pointed out that we need to accelerate the filling of the gaps in China's high-end medical equipment, accelerate the research and development of key core technologies, break through technological equipment bottlenecks, and achieve independent and controllable high-end medical equipment. Surgical robots, large-scale imaging equipment, multimodal control, AI+therapy... China's high-end medical equipment has not only achieved many "hard breakthroughs", but also made great strides forward in "soft power". In a lung cancer surgery at Peking University People's Hospital, a two-dimensional CT image stands up from the screen and accurately simulates the real lesion. Doctors can use voice commands to navigate the surgery to the next "target". Under the support of relevant projects of the Ministry of Science and Technology, the team of Peking University People's Hospital, together with the artificial intelligence team of Tsinghua University, Peking University and the Chinese Academy of Sciences, carried out interdisciplinary research and development, and developed an intelligent auxiliary module for lung cancer surgery, so that the surgical operation can be equipped with intelligent navigation as well as automobile driving. Wang Jun, an academician of the CAE Member and president of the People's Hospital of Peking University, said frankly that in order to achieve individualized design and real-time navigation of patients, the team is committed to finding optimal algorithms and improving the efficiency of labeling. Multiple clinical trials have shown that "navigation" improves surgical accuracy by 8% and reduces error rates by 43%. This is not an isolated case. In the past five years, innovative medical devices for "AI+therapy" in multiple fields have been approved for the first application license. AI+orthopedic surgery, AI+intracranial magnetic resonance imaging, AI+pathological cell diagnosis... "Made in China" medical equipment is not satisfied with turning PET, MRI and other equipment that could not be produced into domestic products, but continuously shaping new miracles with interdisciplinary integration. According to data from the State Administration for Market Regulation, since the 14th Five Year Plan, 265 innovative medical devices, including carbon ion therapy systems, have been approved for market launch. Guo Yanhong, Deputy Director of the National Health Commission, introduced that China has independently developed photon counting CT, which has a spatial resolution 2-3 times higher than traditional CT; Domestic orthopedic surgical robots and endoscopic soft tissue surgical robots have greatly improved surgical accuracy; Products such as extracorporeal membrane oxygenation machines and artificial hearts have been independently developed and put into clinical application, enabling more patients to "use, afford, and use" domestically produced high-end medical equipment. Smart healthcare, weaving a "universal network" for the whole nation. At the end of last year, an Asia Pacific 6D communication satellite located in geostationary orbit connected Lhasa and Beijing. Professor Liu Rong from the People's Liberation Army General Hospital uses precise remote control equipment and high-definition video feedback to operate the surgical robot system in real-time to perform surgical procedures on patients. This is the world's first ultra remote surgery based on satellite communication links. In the past, patients had to travel thousands of miles to large hospitals to see top experts. Nowadays, cutting-edge medical resources are reaching the people in unexpected and intelligent ways. General Secretary Xi Jinping emphasized the need to promote the expansion of high-quality medical resources and balanced regional layout, adhere to the principle of prevention first, strengthen the management of major chronic diseases, and enhance the ability of grassroots disease prevention, treatment, and health management. On August 12th, Shenzhen, the "vanguard" of reform, once again solved the problem and launched the world's first city level medical model cluster "Medical Intelligence Ark". It not only connects data between medical institutions, but also aggregates data from public health institutions and research institutes, making all health and medical data serve people's health and become the "urban medical brain" of Shenzhen. Hou Fanfan, academician of the CAS Member, believes that the large model cluster application has realized the "cloud migration" of high-quality medical capabilities, providing a revolutionary idea for solving the uneven distribution of medical resources. During the 14th Five Year Plan period, medical models focusing on different vertical fields emerged, such as "Beijing Medical Qianxun" and "Futang Baichuan" in Beijing, "Fuxing" and "Qizhi" in Shanghai, and "Mulan" and "Nezha Lingtong" in Wuhan, which integrate millions of clinical data and top expert experience, greatly improving the level of grassroots diagnosis and treatment. The new technology has been able to achieve semantic unity and structured expression of cross institutional data, and the cluster application of national level specialized models has also built a collaborative ecosystem for cross regional medical AI. ”Gong Mengchun, Chief Expert of the National Key R&D Program and Chief Medical Officer of Shenzhou Medical, told reporters that big models are becoming a new solution to solve the problem of "seeking medical treatment" together with telemedicine and smart healthcare. Domestic surgical robots can expand their effectiveness from orthopedics to cardiovascular departments, assisting doctors in completing complex surgeries with extremely high precision and flexibility; AI doctors not only match diagnosis and treatment plans for patients, but also provide health advice based on past medical history; The "medical brain" integrates various professional models to respond to cross disciplinary health needs in a timely manner... Technological innovation effectively enhances the technical level and resource supply of medical and health care, greatly improves diagnosis and treatment effectiveness, and creates a "protective shield" for people's lives and health. Lei Haichao, Secretary of the Party Group and Director of the National Health Commission, stated that the commission will vigorously develop new quality productive forces in the field of health and improve the innovation system of health and science and technology. Promote the transformation of innovative drugs, vaccines, medical equipment and other achievements into clinical applications, promote the in-depth application of artificial intelligence, the Internet and other information technologies in the health field, and provide more tools and means to maintain people's health. (New Society)